OKYO (OKYO Pharma) חוב לטווח קצר להון

OKYO Pharma Limited (OKYO) is developing a biopharmaceutical complex to combat corneal dryness and inflammation using proprietary lipid compounds. This chart illustrates the metric at 0.00. Current R&D research for new eye drops is placing a heavy burden on the budget, keeping operating metrics in the red. The project's profitability relies on insurance payouts and success within the ophthalmology center segment.

This ratio determines the proportion of short-term liabilities relative to equity, allowing for an assessment of the enterprise's financial stability and liquidity risk. The trend of short-term liabilities to equity demonstrates how effectively OKYO Pharma Limited balances borrowed resources to fund the development of innovative drugs for dry eye syndrome without creating excessive pressure on the company's net assets.